Fintel reports that on December 3, 2025, Leerink Partners upgraded their outlook for Spruce Biosciences (NasdaqCM:SPRB) from Market Perform to Outperform.
Analyst Price Forecast Suggests 53.80% Upside
As of November 17, 2025, the average one-year price target for Spruce Biosciences is $137.19/share. The forecasts range from a low of $10.10 to a high of $271.95. The average price target represents an increase of 53.80% from its latest reported closing price of $89.20 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Spruce Biosciences is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -1.65.
What is the Fund Sentiment?
There are 17 funds or institutions reporting positions in Spruce Biosciences. This is an increase of 5 owner(s) or 41.67% in the last quarter. Average portfolio weight of all funds dedicated to SPRB is 0.08%, an increase of 3,808.97%. Total shares owned by institutions increased in the last three months by 42.83% to 2,938K shares. 
The put/call ratio of SPRB is 0.00, indicating a bullish outlook.
What are Other Shareholders Doing?
Carlyle Group holds 2,897K shares representing 270.61% ownership of the company.
Cable Car Capital holds 27K shares representing 2.49% ownership of the company.
Ikarian Capital holds 13K shares representing 1.25% ownership of the company.
Lion Point Capital holds 1K shares representing 0.09% ownership of the company.
Advisor Group Holdings holds 0K shares representing 0.01% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
